The reduction of synj1 provides several beneficial effects in AD such as accelerating Aβ clearance via the lysosomal degradation pathway [30], ameliorating mild traumatic brain injury (TBI)-induced elevation in tau hyper-phosphorylation [31], and rescuing ApoE4-associated cognitive impairments [26]. Here, MAPT is linked to Alzheimer disease.